While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
ORGANIZATION
5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
The pharma industry was “stunned” by the unexpectedly broad product coverage agreed upon for Japan’s first “off-year” re-pricing in April 2021, Toshihiko Miyajima, director general of the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), tells Jiho. Drug prices will…
To read the full story
Related Article
- Japan Govt Should Change Course on Consistent Price Cuts for On-Patent Drugs: FPMAJ Exec
March 22, 2021
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- Chuikyo OKs Revised NHI Pricing Rules for FY2021 Drug Re-Pricing
January 14, 2021
- 3 Pharma Groups Rap Off-Year Drug Re-Pricing Plan; Generic Industry Frets Impact on Stable Supplies
December 21, 2020
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
ORGANIZATION
- Exclude Patented Drugs from Off-Year Price Revision: JPMA, PhRMA, EFPIA
November 24, 2022
- Citizen’s Group Renews Opposition to Emergency Approval of Shionogi COVID-19 Pill
November 22, 2022
- Increasing Number of Lawmakers Are Against Off-Year Price Revision: JPMA Director General
November 18, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
- As Arrival of Alzheimer’s Meds Nears, Experts Talk over Financial Impact and ROI: Lilly/PhRMA Forum
November 9, 2022
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…